JP7100362B2 - グループｉｉ代謝型グルタミン酸受容体のアロステリックモジュレーターとしての置換三環式１，４－ベンゾジアゼピノン誘導体 - Google Patents

グループｉｉ代謝型グルタミン酸受容体のアロステリックモジュレーターとしての置換三環式１，４－ベンゾジアゼピノン誘導体 Download PDF

Info

Publication number
JP7100362B2
JP7100362B2 JP2018544438A JP2018544438A JP7100362B2 JP 7100362 B2 JP7100362 B2 JP 7100362B2 JP 2018544438 A JP2018544438 A JP 2018544438A JP 2018544438 A JP2018544438 A JP 2018544438A JP 7100362 B2 JP7100362 B2 JP 7100362B2
Authority
JP
Japan
Prior art keywords
alkyl
methyl
benzo
diazepine
cyclopropane
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2018544438A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019504108A (ja
JP2019504108A5 (enExample
Inventor
シャン，シュテファン
マイヤー，スタニスラス
マントー，バティスト
Original Assignee
ドメイン・セラピューティクス
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ドメイン・セラピューティクス filed Critical ドメイン・セラピューティクス
Publication of JP2019504108A publication Critical patent/JP2019504108A/ja
Publication of JP2019504108A5 publication Critical patent/JP2019504108A5/ja
Application granted granted Critical
Publication of JP7100362B2 publication Critical patent/JP7100362B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A61K31/5517—1,4-Benzodiazepines, e.g. diazepam or clozapine condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
JP2018544438A 2015-11-13 2016-11-11 グループｉｉ代謝型グルタミン酸受容体のアロステリックモジュレーターとしての置換三環式１，４－ベンゾジアゼピノン誘導体 Expired - Fee Related JP7100362B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP15194611 2015-11-13
EP15194611.8 2015-11-13
PCT/GB2016/053550 WO2017081483A1 (en) 2015-11-13 2016-11-11 Substituted tricyclic 1,4-benzodiazepinone derivatives as allosteric modulators of group ii metabotropic glutamate receptors

Publications (3)

Publication Number Publication Date
JP2019504108A JP2019504108A (ja) 2019-02-14
JP2019504108A5 JP2019504108A5 (enExample) 2019-12-19
JP7100362B2 true JP7100362B2 (ja) 2022-07-13

Family

ID=54542126

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018544438A Expired - Fee Related JP7100362B2 (ja) 2015-11-13 2016-11-11 グループｉｉ代謝型グルタミン酸受容体のアロステリックモジュレーターとしての置換三環式１，４－ベンゾジアゼピノン誘導体

Country Status (10)

Country Link
US (1) US11008323B2 (enExample)
EP (1) EP3374360A1 (enExample)
JP (1) JP7100362B2 (enExample)
KR (1) KR20180097542A (enExample)
CN (1) CN108834415B (enExample)
AU (1) AU2016354661B2 (enExample)
BR (1) BR112018009550A2 (enExample)
CA (1) CA3004680A1 (enExample)
IL (1) IL259214B (enExample)
WO (1) WO2017081483A1 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110769830A (zh) * 2017-05-12 2020-02-07 马瓦隆治疗有限公司 作为ii组代谢型谷氨酸受体的别构调节剂的取代的杂环化合物
CN108084187A (zh) * 2017-12-15 2018-05-29 宜昌人福药业有限责任公司 苯并二氮杂*类氢化物
CN108003164A (zh) * 2017-12-15 2018-05-08 宜昌人福药业有限责任公司 苯并二氮杂*类化合物
WO2020223701A1 (en) * 2019-05-02 2020-11-05 The Broad Institute, Inc. Methods for treating neurodevelopmental disorders
CN110172068A (zh) * 2019-06-05 2019-08-27 河南龙湖生物技术有限公司 具有抗肿瘤活性的苯并噻唑类化合物及其制备方法和应用
WO2021226208A2 (en) 2020-05-05 2021-11-11 Nuvalent, Inc. Heteroaromatic macrocyclic ether chemotherapeutic agents
KR102698413B1 (ko) 2020-05-05 2024-08-26 뉴베일런트, 아이엔씨. 헤테로방향족 거대환식 에터 화학치료제
TW202320768A (zh) 2021-10-01 2023-06-01 美商努法倫特公司 雜芳族大環醚化合物之固體形式、醫藥組成物及製備
WO2026006700A1 (en) * 2024-06-28 2026-01-02 Regents Of The University Of Michigan Pyrrolo[1,2-a]-azocine analogues as iap antagonists
CN118993997A (zh) * 2024-10-23 2024-11-22 浙江雅辰药物科技股份有限公司 一种3-溴-2-苯基吡啶的制备方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014117919A1 (en) 2013-02-04 2014-08-07 Merck Patent Gmbh Positive allosteric modulators of mglur3

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4130716A (en) 1977-03-07 1978-12-19 Hoffmann-La Roche Inc. Pyrazolo benzodiazepines
US4263428A (en) 1978-03-24 1981-04-21 The Regents Of The University Of California Bis-anthracycline nucleic acid function inhibitors and improved method for administering the same
DE3169595D1 (en) 1980-11-10 1985-05-02 Gersonde Klaus Method of preparing lipid vesicles by ultrasonic treatment, the use of this method and apparatus for its application
US4485045A (en) 1981-07-06 1984-11-27 Research Corporation Synthetic phosphatidyl cholines useful in forming liposomes
EP0088046B1 (de) 1982-02-17 1987-12-09 Ciba-Geigy Ag Lipide in wässriger Phase
DE3218121A1 (de) 1982-05-14 1983-11-17 Leskovar, Peter, Dr.-Ing., 8000 München Arzneimittel zur tumorbehandlung
EP0102324A3 (de) 1982-07-29 1984-11-07 Ciba-Geigy Ag Lipide und Tenside in wässriger Phase
US4544545A (en) 1983-06-20 1985-10-01 Trustees University Of Massachusetts Liposomes containing modified cholesterol for organ targeting
HUT35524A (en) 1983-08-02 1985-07-29 Hoechst Ag Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance
DE3486459D1 (de) 1983-09-26 1997-12-11 Udo Dr Med Ehrenfeld Mittel und Erzeugnis für die Diagnose und Therapie von Tumoren sowie zur Behandlung von Schwächen der zelligen und humoralen Immunabwehr
EP0143949B1 (en) 1983-11-01 1988-10-12 TERUMO KABUSHIKI KAISHA trading as TERUMO CORPORATION Pharmaceutical composition containing urokinase
FI880814A7 (fi) 1987-03-10 1988-09-11 Hoffmann La Roche Imidazodiazepin-derivat.
MX2009007053A (es) 2006-12-28 2009-07-09 Abbott Lab Inhibidores de poli (adp-ribosa) polimerasa.

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014117919A1 (en) 2013-02-04 2014-08-07 Merck Patent Gmbh Positive allosteric modulators of mglur3

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
IL FARMACO，1998年，53，305-311
Tetrahedron Letters，2011年，52，541-543
Tetrahedron Letters，2015年，56，1030-1033
Tetrahedron，2009年，65，8956-8960

Also Published As

Publication number Publication date
US20180346468A1 (en) 2018-12-06
JP2019504108A (ja) 2019-02-14
BR112018009550A2 (pt) 2018-11-06
EP3374360A1 (en) 2018-09-19
AU2016354661B2 (en) 2020-12-10
IL259214B (en) 2021-09-30
CA3004680A1 (en) 2017-05-18
CN108834415B (zh) 2021-12-24
IL259214A (en) 2018-07-31
AU2016354661A1 (en) 2018-06-07
KR20180097542A (ko) 2018-08-31
US11008323B2 (en) 2021-05-18
WO2017081483A1 (en) 2017-05-18
CN108834415A (zh) 2018-11-16

Similar Documents

Publication Publication Date Title
JP7241810B2 (ja) Ｈｐｋ１阻害剤およびそれを用いる方法
US11008323B2 (en) Substituted tricyclic 1,4-benzodiazepinone derivatives as allosteric modulators of group II metabotropic glutamate receptors
JP7299837B2 (ja) 化合物、組成物、および使用方法
JP5806672B2 (ja) 新規オキシム誘導体及び代謝型グルタミン酸受容体のアロステリック調節因子としての利用
JP2013501013A (ja) 代謝調節型グルタミン酸受容体モジュレーター
CN112566906A (zh) 取代的喹唑啉酮衍生物和它们作为mglur4的正变构调节剂的用途
CN120265619A (zh) 作为pi3k抑制剂的异喹诺酮
JP2021519316A (ja) Ｔｌｒ２シグナル伝達の調節剤としての化合物
WO2016104434A1 (ja) 複素環化合物
KR20150021120A (ko) 헤테로아릴 화합물 및 이의 이용 방법
TW202024020A (zh) 治療神經退化性疾病之方法
CN121591715A (zh) 作为vav1降解剂的二酮联苯基类化合物及其用途
JP2015527993A (ja) アリールエチニル誘導体
US11472806B2 (en) Substituted heterocyclic compounds as allosteric modulators of group II metabotropic glutamate receptors
CN107223126A (zh) 作为ii组代谢型谷氨酸受体的别构调节剂的取代的吡唑并喹唑啉酮和吡咯并喹唑啉酮
CN110709401A (zh) 杂环化合物
WO2024120519A1 (zh) Tead抑制剂、其制备方法和在医学上的应用
TW201307300A (zh) 趨代謝性麩胺酸受體調節劑

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20191111

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20191111

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20201016

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20201015

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20210118

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210316

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20210317

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210831

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20211130

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20220131

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220217

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20220615

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20220624

R150 Certificate of patent or registration of utility model

Ref document number: 7100362

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

LAPS Cancellation because of no payment of annual fees